ICER Publishes Methodology on Evaluating Unsupported Drug Price Increases

ICER has released a protocol detailing how it analyses UPIs (Unsupported Price Increases) for prescription drugs in the United States. ICER also welcomes input from the public when it comes to choosing drugs for evidence review and analyzing price increases, as well as from manufacturers. ICER had previously released UPI reports for 2019.

“Based on input from a multi-stakeholder advisory group — spanning patient advocates, life sciences companies, public and private payers, and health economists — this updated Protocol further hones how price increases shall be identified, how manufacturers can engage with ICER throughout the process, and how the clinical evidence will be assessed.” Read more here.

(Source: ICER, 4/12/21)